Journal Home
Search for

Volume 19, Issue 12, Pages 833-836 (December 2009)


View previous. 8 of 19 View next.

Antisense oligonucleotide therapeutics for iron–sulphur cluster deficiency myopathy

Gittan KollbergCorresponding Author Informationemail address, Elisabeth Holme

Received 3 July 2009; received in revised form 8 September 2009; accepted 30 September 2009.

Abstract 

Iron–sulphur cluster deficiency myopathy is caused by a deep intronic mutation in ISCU resulting in inclusion of a cryptic exon in the mature mRNA. ISCU encodes the iron–sulphur cluster assembly protein IscU. Iron–sulphur clusters are essential for most basic redox transformations including the respiratory-chain function. Most patients are homozygous for the mutation with a phenotype characterized by a non-progressive myopathy with childhood onset of early fatigue, dyspnoea and palpitation on trivial exercise. A more severe phenotype with early onset of a slowly progressive severe muscle weakness, severe exercise intolerance and cardiomyopathy is caused by a missense mutation in compound with the intronic mutation. Treatment of cultured fibroblasts derived from three homozygous patients with an antisense phosphorodiamidate morpholino oligonucleotide for 48h resulted in 100% restoration of the normal splicing pattern. The restoration was stable and after 21days the correctly spliced mRNA still was the dominating RNA species.

Department of Clinical Chemistry, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden

Corresponding Author InformationCorresponding author. Address: Department of Clinical Chemistry, Sahlgrenska University Hospital, Bruna stråket 16, SE-413 45 Göteborg, Sweden. Tel.: +46 31 3427971; fax: +46 31 827610.

PII: S0960-8966(09)00651-8

doi:10.1016/j.nmd.2009.09.011


View previous. 8 of 19 View next.